Established in 1888, Abbott Labs is a diversified healthcare conglomerate with a global presence. The firm operates in four main segments: Nutritionals, Diagnostic, Vascular and Generic Pharmaceuticals. It also has a portfolio of diabetes products and medical optics. We treat this as the fifth segment within the firm.
The nutritional segment includes pediatric, adult, healthy living and sports nutrition products such as infant formulas, snack bars and meal replacement shakes. The diagnostics segment includes systems and tests used for screening for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases and infectious diseases such as hepatitis and HIV.
The vascular segment includes minimally invasive medical devices for heart diseases, strokes, carotid artery diseases, and other serious vascular conditions. The generic pharmaceuticals segment includes a broad line of generic drugs that are manufactured worldwide and sold outside the U.S.
The story of Novo Nordisk South Africa began in 1959 in Johannesburg. It was among the first affiliates outside of Denmark, with insulin and anti-infectives produced locally. To what extent…
You have worked at Roche for several years as Business unit Manager. Therefore you are familiar with the strategy of the company and the intricacies of the job. The new…
Having spent two months as the head of Novartis South Africa, what is your first assignment as General Manager, could you share with our readers what were the surprises for…
Mr. Miller, you have been Vice President and Managing Director of Mylan’s operations in South Africa since 2008. What mission were you assigned back then, and in those three years,…
South Africa carries one of the world’s most disproportionate disease burdens, the worst of so-called westernised diseases, such as cardiac disease, diabetes etc on the one hand and the developmental…
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
South Africa is at the moment one of the world’s most exciting and dynamic markets at the moment as Mr. Omar Ehsan was telling us, the most exciting market he…
Could you introduce to our readers MC Pharma’s business model in the South African market as well as the main milestones in the company’s development over the recent years? MC…
Mr. Daniel, after working with Pfizer Australia, working in Hong Kong as Regional Marketing Director for the Asian operation and in Japan, you have been the first South African appointed…
Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of…